Telehealth Alternatives to Ozempic & Wegovy (2026)
Compare reviewed GLP-1 weight loss providers, billing commitments, and the treatments their links actually offer.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Compare the options first
Full comparison & price terms ↓A short preview in editorial order—not a guarantee of the cheapest total bill. Read the commitment terms before choosing.
From $198/mo
Lower listed rate · not necessarily monthly billing
Includes coaching
The Ranking
WellMedr
Compounded GLP-1 care with semaglutide shown at $49/mo or tirzepatide at $89/mo with 12-month prepayment; $99/$129 month to month. Verified affiliate coverage is weight loss only.
Editor’s take: WellMedr is our featured value-led compounded GLP-1 option, not a recommendation for unrelated men's-health or hair-loss treatment. Its public Trustpilot profile displayed 4.6/5 from 1,963 reviews when checked September 27, 2026; customer opinions do not establish clinical effectiveness. Recorded price terms were semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month. Compounded medications are not FDA-approved finished drugs. Confirm the exact prescription, pharmacy, dose progression, cancellation terms, and total commitment with the clinician before paying.
Full review →
SkinnyRx
Clinician-guided GLP-1 platform with both compounded and brand-name access plus overnight shipping.
Editor’s take: Premium positioning, premium catalog. If you want maximum optionality across GLP-1 modalities, this is the deepest menu on the site. The premium catalog comes at a premium price. If you want maximum optionality across GLP-1 modalities, SkinnyRx is the deepest menu on the site; if you want the lowest cost, look at Trimi or HealthRx.
Full review →
Direct Meds
Compounded GLP-1 clinic with transparent pricing and dedicated nurse support.
Editor’s take: Direct Meds is easier to compare than a program that separates its membership fee from medication, provided the public $249 and $297 starting points match the treatment path you are offered. Skip it if you specifically want brand-name GLP-1 access or in-state pickup.
Full review →
Shed Rx
GLP-1 clinic offering injections, oral semaglutide, drops, and lozenges plus brand-name Wegovy and Zepbound.
Editor’s take: A reasonable mid-priced pick when delivery flexibility matters. Verify auto-billing terms before signing up given mixed reports. Verify auto-billing terms before signing up given mixed reviews on cancellation. If delivery flexibility is your priority, compare ShedRx against Breeze Meds which also offers sublingual tirzepatide.
Full review →
Women-focused telehealth combining compounded GLP-1 weight loss with HRT support.
Editor’s take: A focused women's health pick. If you only want GLP-1, you'll find cheaper; if you want both GLP-1 and HRT in one clinic, this is one of the cleanest options on the list. If you only want GLP-1 without hormonal support, a lower-cost specialist like Trimi or HealthRx will be more cost-effective. If you want both GLP-1 and HRT in one clinic, Gala Health is one of the cleanest options available.
Full review →
FuturHealth
GLP-1 weight-loss platform combined with personalised nutrition and fitness coaching.
Editor’s take: Coaching is the differentiator. If you're going to use it, FuturHealth pulls ahead of cheaper, drug-only competitors. If you won't, save the money.
Full review →
Flexible, medically guided compounded GLP-1 weight loss with transparent monthly pricing.
Editor’s take: Honest, simple, and focused. No brand-name GLP-1 access is the main trade-off, but for cost-conscious first-time users who just want a guided compounded GLP-1 program without upsells or complexity, that trade-off is rational. Transparent monthly pricing with no hidden fees is a genuine differentiator in a category where pricing opacity is common.
Full review →
Refills
Multi-category telehealth platform covering GLP-1, ED, hair loss, and longevity peptides with no membership fees and flat dosage pricing.
Editor’s take: A versatile multi-category platform with a competitive GLP-1 entry price and no dose-tier price increases. The breadth of treatments (GLP-1, ED, hair, longevity) makes it a practical single-provider option, though the FDA warning letter regarding compounded semaglutide advertising is worth noting.
Full review →2026 Price Comparison. Published Price Terms
Compare the lower and higher listed rates, then read the billing conditions. A listed monthly equivalent may require prepayment; visits, medication, membership, or shipping can cost extra.
Recorded price-check dates: 26 June 2026 – 13 July 2026. Per-provider dates below; these are not a guarantee of today's checkout price.
Rates use different billing terms and are not necessarily all-in or month-to-month. Confirm total charges and cancellation terms. Compounded medications are not FDA-approved finished drugs; pharmacy type alone does not establish legality or clinical suitability.
4 providers · Trustpilot scores are customer opinions, not treatment results.
| Provider & billing terms | Lower listed rate | Higher listed rate | Pharmacy | Reviews & price check | Actions |
|---|---|---|---|---|---|
| SkinnyRx | Lower listed rateFrom $149/mo | Higher listed rateFrom $249/mo | PharmacyBrand + compounded | 4.8/5 5,335 reviews 26 June 2026 | Go SkinnyRxRead full review |
| FuturHealth Includes coaching | Lower listed rateFrom $198/mo | Higher listed rateFrom $299/mo | PharmacyCompounded 503A | 4.7/5 15,774 reviews 26 June 2026 | Go FuturHealthRead full review |
| Found Health | Lower listed rateFrom $129/mo | Higher listed rateFrom $349/mo | PharmacyBrand + compounded | 3.7/5 729 reviews 26 June 2026 | Go FoundRead full review |
| Telos Rx Semaglutide from $49 first month | Lower listed rateFrom $49/mo | Higher listed rateFrom $199/mo | PharmacyCompounded 503A | 4.9/5 3 reviews 13 July 2026 | Go Telos RxRead full review |
Provider links may earn a commission. Rate sorting compares the displayed numbers, not equivalent treatment plans or total commitments. How we check price terms →
What to know before choosing
Ozempic and Wegovy (both semaglutide) remain the most recognised names in GLP-1 weight loss, but cash-pay pricing near $1,000–$1,350/month, insurance hurdles, and shortages send many people searching for an alternative. This guide focuses on the switching decision: your realistic options, what each costs, and which fits your situation — not just a place to buy. Every alternative below routes to a provider we've verified.
Semaglutide — the molecule in both Wegovy and Ozempic — produced 14.9% mean weight loss in the STEP 1 trial (NEJM 2021). As with tirzepatide, the obstacle is usually access, not effectiveness: brand-name semaglutide costs roughly $1,000–$1,350/month cash-pay, and insurance coverage for weight loss is inconsistent.
If you're switching, the realistic paths are: (1) stay on brand-name semaglutide but move to a telehealth provider with lower cash pricing; (2) switch to compounded semaglutide from a 503A pharmacy under the personalisation exception, typically $80–$249/month; (3) switch molecules to tirzepatide (Zepbound/Mounjaro or compounded), which showed larger average weight loss in trials; or (4) move to an oral GLP-1 pill. Each path differs in cost, legal status, and clinical trade-off.
Below we rank the telehealth providers that make each switch realistic, then map which alternative fits which scenario — cost, insurance denial, supply, or a molecule change. No provider paid for placement.
Methodology
We scored each alternative provider on four axes: semaglutide access (brand-name and/or compounded), price transparency at every dose tier, pharmacy disclosure (503A vs 503B, named partner), and clinical oversight. We then mapped each option to the switching scenario it best solves. Affiliate-offer eligibility also affects which providers appear and their order, as our methodology explains.
How to Actually Choose an Ozempic or Wegovy Alternative
Ozempic and Wegovy are the most recognised names in GLP-1 weight loss, which is exactly why so many people overpay for them. The brand premium is real, and for a large share of patients there's a cheaper or more available alternative that uses the same molecule. But 'alternative' covers several different moves — a cheaper semaglutide source, a different molecule, or an oral pill — and they aren't interchangeable. Here's how to choose based on your actual situation rather than the loudest ad.
Start With Why You're Switching
Semaglutide is the molecule inside both Ozempic (diabetes-indicated) and Wegovy (obesity-indicated). If you're switching, the first question is whether you want to stay on semaglutide or change molecules. Staying on semaglutide but cutting cost points to compounded semaglutide ($99–$299/month) or a lower cash-pay brand source. Wanting stronger results points to tirzepatide (Zepbound/Mounjaro or compounded), which produced larger average weight loss in trials. Wanting to avoid injections points to an oral GLP-1 pill. Each is a genuinely different path with a different cost and trade-off.
A common and avoidable error is switching from Ozempic to Wegovy (or vice versa) expecting a different result — they're the same drug at different labeled doses. If your goal is weight loss and you're on Ozempic, the relevant move is usually to an obesity-indicated or compounded semaglutide at a weight-management dose, not a lateral hop between two semaglutide brands. Define whether you're optimising for price, potency, or route before you start comparing providers.
The Insurance Angle Most Pages Ignore
Ozempic is frequently covered for type 2 diabetes but denied when used off-label for weight loss; Wegovy is covered only by plans that include an obesity-drug benefit. That distinction drives a lot of the switching traffic: patients prescribed Ozempic for weight loss get hit with the full cash price once the plan flags the off-label use. If that's you, the cheaper-correct answer is usually compounded semaglutide rather than paying retail for brand Ozempic.
If your plan does include an obesity benefit but denied you on BMI or step-therapy grounds, an appeal can restore brand Wegovy coverage that's cheaper than cash-pay once your copay applies — and the brand-name-capable providers above can help assemble that paperwork. If your plan excludes weight-loss drugs entirely, skip the appeal and price compounded semaglutide directly. The point is to match the move to the denial reason instead of defaulting to whichever provider markets hardest.
What Compounded Semaglutide Actually Is
Compounded semaglutide is the same active molecule as Ozempic and Wegovy, prepared by a state-licensed compounding pharmacy rather than by Novo Nordisk. It is not an FDA-approved finished drug. With semaglutide off the FDA shortage list, its availability now depends on the 503A personalisation exception, which requires documented clinical justification — a narrower legal basis than during the shortage period. Any provider still marketing it should be transparent about how they meet that exception.
For a switcher, compounded semaglutide is the cheapest like-for-like alternative to brand Wegovy/Ozempic, but the same diligence applies as with tirzepatide: prefer clinics that name their pharmacy partner, disclose 503A versus 503B sourcing, and provide clinician-controlled titration rather than letting you self-escalate. The lowest headline price is not worth an unnamed pharmacy and no clinical oversight.
The short version: Ozempic and Wegovy carry a brand premium that a cheaper semaglutide source often eliminates, but only switch molecules or routes if price isn't your real constraint. Identify whether you're after a lower price, more potency, or a needle-free option — then use the ranking above to act on it.
What the Studies Actually Show
Ozempic and Wegovy both contain semaglutide; the alternatives below are either the same molecule (compounded semaglutide) or tirzepatide (Zepbound/Mounjaro and compounded). The figures summarise the pivotal Phase 3 trials for both molecules.
| Endpoint | Finding |
|---|---|
| Mean weight loss (STEP 1, 68 weeks, 2.4 mg)1 | −14.9% body weight vs −2.4% placebo in adults with overweight/obesity without diabetes |
| Cardiovascular outcomes (SELECT, ~40 months)2 | 20% relative risk reduction in major adverse cardiovascular events (MACE) in adults with established CV disease and overweight/obesity |
| GI side effects (FDA prescribing information)3 | Nausea ≥10%, diarrhea ≥10%, vomiting ≥10%, constipation ≥10%; most cases mild–moderate and dose-dependent |
| Mean weight loss (SURMOUNT-1, 72 weeks, 15 mg)6 | −20.9% body weight vs −3.1% placebo in adults with obesity without diabetes |
| Mean weight loss with T2D (SURMOUNT-2, 72 weeks, 15 mg)7 | −14.7% body weight in adults with type 2 diabetes |
Frequently Asked Questions
What is the best telehealth alternative to Wegovy?
It depends on your reason for switching. For cost, compounded semaglutide from a 503A pharmacy ($80–$249/month) is the cheapest like-for-like alternative. To stay on an FDA-approved product, several telehealth providers offer brand-name Wegovy at lower cash-pay rates than retail. If you want stronger average results, switching to tirzepatide (Zepbound/Mounjaro or compounded) is the common upgrade path.
Is there a cheaper alternative to Ozempic?
Yes. Compounded semaglutide (same molecule, $80–$249/month under the personalisation exception) is the most direct cheaper option. Note that Ozempic is FDA-approved for type 2 diabetes rather than weight loss; for weight management, Wegovy or compounded semaglutide are the on-label and lower-cost routes respectively.
Can I switch from Ozempic or Wegovy to compounded semaglutide?
Often yes, with a prescriber's documented clinical justification under the personalisation exception (for example a customised dose or a documented intolerance to an inactive ingredient). A telehealth clinician can assess suitability and coordinate the switch. Compounded products are not FDA-approved finished drugs.
Should I switch from semaglutide to tirzepatide?
Tirzepatide (Zepbound/Mounjaro) showed larger average weight loss than semaglutide in trials, so it's a common upgrade for people who have plateaued or want stronger results. However, it can be more expensive and stock can vary. The decision is individual and should be made with a prescriber.
Are compounded semaglutide alternatives legal in 2026?
503A compounding of semaglutide remains legal under the personalisation exception, which requires a documented clinical justification from the prescriber. The FDA ended the official semaglutide shortage in 2025, so mass-scale compounding without that justification is no longer permitted. Confirm your provider's pharmacy licensure before switching.
- STEP 1 — NEJM 2021 · Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
- SELECT — NEJM 2023 · Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221–2232.
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SURMOUNT-2 — Lancet 2023 · Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613–626.
- SURMOUNT-OSA — NEJM 2024 · Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193–1205.
- SURPASS — program summary · Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.
RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.